Clinical trial

Comparing Semaglutide Versus Placebo on Intestinal Barrier Function in Type 2 Diabetes Mellitus (SIB)

NCT04979130

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2022-01-01

PhasePHASE4

Study timeline

Study start (actual)2022-01-01Date precision: day

Registry last updated2025-03-20

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Type 2 Diabetesunresolved

Chronic Inflammationunresolved

Intestinal Permeabilityunresolved

Interventions

SemaglutideDRUG · verified · RxNorm: semaglutide

PlaceboDRUG

Sponsors & collaborators

University of Colorado, Denverlead sponsor

Novo Nordisk A/Scollaborator

Mapped research locations

AuroraColorado, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04979130 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.